I think you just have to be honest and fair with yourself. Throw the fact that it’s a really great device and working with patients is awesome out the window. The study wasn’t positive and things are going to change significantly. Revenue will shrink and insurance companies will absolutely refuse to pay for mi patients with a low ef.
Do you believe that company will do the right thing and lower revenue expectations, and guarantee people a more dependable income? Will they float this very large (even by pharma standards much less device) sales force through a tough time or will they cut a large percentage of internal and customer facing employees? Will the ADs and VPs, some of whom are an absolute embarrassment to the industry, suddenly change and become positive forces for good?
I for one have worked at other device and pharma companies with better leaders and better cultures and seen this end badly. I think it’s foolish to hope for a different outcome here.